Cargando…

The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses

Non-small-cell lung cancer (NSCLC) is the second most diagnosed type of malignancy and the first cause of cancer death worldwide. Despite recent advances, the treatment of choice for NSCLC patients remains to be chemotherapy, often showing very limited effectiveness with the frequent occurrence of d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciccone, Giuseppe, Ibba, Maria Luigia, Coppola, Gabriele, Catuogno, Silvia, Esposito, Carla Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093969/ https://www.ncbi.nlm.nih.gov/pubmed/37047090 http://dx.doi.org/10.3390/ijms24076121

Ejemplares similares

Advances in Oligonucleotide Aptamers for NSCLC Targeting
por: Rotoli, Deborah, et al.
Publicado: (2020)

Selection of RNA aptamers targeting hypoxia in cancer
por: Nuzzo, Silvia, et al.
Publicado: (2022)

Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts
por: Santana-Viera, Laura, et al.
Publicado: (2020)

Combined Targeting of Glioblastoma Stem-Like Cells by Neutralizing RNA-Bio-Drugs for STAT3
por: Esposito, Carla Lucia, et al.
Publicado: (2020)

Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells
por: Esposito, Carla Lucia, et al.
Publicado: (2014)

Nucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic Option
por: Catuogno, Silvia, et al.
Publicado: (2018)

Aptamer Cell-Based Selection: Overview and Advances
por: Catuogno, Silvia, et al.
Publicado: (2017)

Coupling Aptamers to Short Interfering RNAs as Therapeutics
por: Cerchia, Laura, et al.
Publicado: (2011)

Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives
por: Esposito, Carla Lucia, et al.
Publicado: (2018)

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
por: Catuogno, Silvia, et al.
Publicado: (2016)

STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
por: Esposito, Carla Lucia, et al.
Publicado: (2017)

Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer
por: Nuzzo, Silvia, et al.
Publicado: (2019)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
por: Catuogno, Silvia, et al.
Publicado: (2019)

Delivery of therapeutic small interfering RNA: The current patent-based landscape
por: Chen, Yu, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Small Molecules: Therapeutic Application in Neuropsychiatric and Neurodegenerative Disorders
por: Schiavone, Stefania, et al.
Publicado: (2018)

Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression
por: Quirico, Lorena, et al.
Publicado: (2020)

An anti-PDGFRβ aptamer for selective delivery of small therapeutic peptide to cardiac cells
por: Romanelli, Alessandra, et al.
Publicado: (2018)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics
por: Scharner, Juergen, et al.
Publicado: (2021)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Recent Advance in Biosensors for microRNAs Detection in Cancer
por: Catuogno, Silvia, et al.
Publicado: (2011)

Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
por: Lazzari, Chiara, et al.
Publicado: (2023)

Current landscape of therapeutic EUS: Changing paradigms in gastroenterology practice
por: Vanella, Giuseppe, et al.
Publicado: (2022)

Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect
por: Yan, Xing, et al.
Publicado: (2022)

Targeting Insulin Receptor with a Novel Internalizing Aptamer
por: Iaboni, Margherita, et al.
Publicado: (2016)

Identification of a novel RNA aptamer that selectively targets breast cancer exosomes
por: Esposito, Carla Lucia, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
por: Tostes, Katiane, et al.
Publicado: (2023)

Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect [Corrigendum]
Publicado: (2023)

CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
por: Wald, Ori
Publicado: (2018)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Current progress in the derivation and therapeutic application of neural stem cells
por: Tang, Yuewen, et al.
Publicado: (2017)

Current Progress in Conductive Hydrogels and Their Applications in Wearable Bioelectronics and Therapeutics
por: Khan, Bangul, et al.
Publicado: (2023)

Therapeutics in paediatric genetic diseases: current and future landscape
por: Koh, Ai Ling, et al.
Publicado: (2023)

Research Progress on Therapeutic Targeting of Cancer-Associated Fibroblasts to Tackle Treatment-Resistant NSCLC
por: Li, Chenxin, et al.
Publicado: (2022)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lsduscm48dv10soiajimn8n1i